

18 2002 E	IN THE UNITED STATES PATENT AND (Case No. 00-713-i13	
In the Applic	cation of:)
	Mirkin et al.) Examiner: J. Riley
Serial No.	09/975,384)) Common Ant Harita 1656
Filed:	October 11, 2001) Group Art Unit: 1656
For:	Nanoparticles Having Oligonucleotides Attached Thereto and Uses Therefor) Confirmation No.: 9813
Box SEQUE Commission Washington,	er for Patents	RECEIVED
Sir:	TRANSMITTAL LE	TECH CENTER 1600/2900
In reg	gard to the above identified application:	
1.	We are transmitting herewith the attached	
	 a. Response to Notice to Comply dated October 31, 2001 b. Copy of the Notice to Comply c. Sequence Listing (paper and computer readable form on 3.5" diskette) d. Return Receipt Postcard 	
2.	2. With respect to additional fees:	
X A. No additional fee is required B. Attached is a check in the amount of \$		
	eneral Authorization: Please charge any additi nt No. 13-2490. A duplicate copy of this sheet is	• •
Letter :	ERTIFICATE UNDER 37 CFR 1.8: The unde and the paper, as described in paragraph 1 herei Postal Service with sufficient postage as first c	nabove, are being deposited with the United

SEQUENCE, Commissioner for Patents, Washington, D.C. 20231 on this 20 day of December, 2001.

Emily Miao

Reg. No. 35,285

DISK TO STIC DATE: JAN 18 2002

PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-713-i13)

Mirkin et al.

Serial No. 09/975,384

Filed: October 11, 2001

PATENT

PATENT

PATENT

PATENT

France:

October 11, 2001

Nanoparticles Having Oligonucleotides

Attached Thereto and Uses Therefor

RESPONSE TO NOTICE TO COMPLY

RECEIVED

FEB U 4 2002

TECH CENTER 1600/2900

Confirmation No.: 9813

Box SEQUENCE Commissioner for Patents Washington, D.C. 20231

Sir:

For:

This is in response to the Notice to Comply mailed October 31, 2001. Attached is a paper copy of a Sequence Listing and 3.5" diskette containing a computer readable copy of the Sequence Listing in accordance with 37 C.F.R. § 1.821(e). In accordance with 37 C.F.R. §§ 1.821-1.825, the computer readable copy is identical to the paper copy filed with the disclosure of the application and the attached Sequence Listing. No new matter has been added to the application as a result of this submission.

Prompt consideration and entry of this response is respectfully requested.

Respectfully submitted,


Date: December 2001

By:

Emily Miao

Reg. No. 35,285

Chicago, IL 60606 Telephone: (312) 913-0001 Facsimile: (312) 913-0002



COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/975,384

10/11/2001

Chad A. Mirkin

00-713-i13

CONFIRMATION NO. 9813

Date Mailed: 10/31/2001

FORMALITIES LETTER

OC000000007003064

Emily Miao McDonnell Boehnen Hulbert & Berghoff 32nd Floor 300 S. Wacker Drive Chicago, IL 60606

> NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and. where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. To Purchase Patentin Software, call (703) 306-2600

 For Patentin Software Program Help, call (703) 306-4119 or e-mail at FECH CENTER 1600 patin 21 help@uspto.gov Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

Customer Service Center

Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE